Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medclair ABNGM:MCLR +3.21%71 3-Year EBITDA Growth Rate is 180.20% as of Mar. 2026, which is 237% above its 10-year median of 53.40. GuruFocus rates NGM:MCLR with a GF Score™ of 71/100 and a GF Value™ of kr2.38 (Modestly Overvalued). Among 692 Medical Devices & Instruments companies, Medclair AB ranks better than 99.71% on this metric.
During the past 12 months, Medclair AB's average EBITDA Per Share Growth Rate was 192.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 180.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Medclair AB was 180.20% per year. The lowest was 2.80% per year. And the median was 53.40% per year.
Medclair AB (NGM:MCLR) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Medclair AB 3-Year EBITDA Growth Rate Related Terms
NGM:MCLR vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Medclair AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medclair AB 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medclair AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Medclair AB's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 180.20% mean?
Medclair AB (NGM:MCLR) has a 3-Year EBITDA Growth Rate of 180.20% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Medclair AB and its competitors. This is 237% above median its historical median of 53.40. Over the past decade, Medclair AB's 3-Year EBITDA Growth Rate has ranged from 2.80 to 180.20. According to the industry distribution chart, Medclair AB ranks #2 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 0.3%.
Is Medclair AB's 3-Year EBITDA Growth Rate too high?
Medclair AB's current 3-Year EBITDA Growth Rate of 180.20% is 237% above median its 10-year median of 53.40. Over the past 10 years, this metric has ranged from a low of 2.80 to a high of 180.20. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. Medclair AB's value of 180.20% is 2097.6% above this industry median. Based on the distribution chart, Medclair AB ranks #2 out of 692 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medclair AB has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medclair AB's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medclair AB ranks #2 out of 692 companies for 3-Year EBITDA Growth Rate. This places Medclair AB in the top 0% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.20. Medclair AB's value of 180.20% is 2097.6% above this benchmark. Historically, Medclair AB's own 3-Year EBITDA Growth Rate has ranged from 2.80 to 180.20 over the past decade. While the company's 10-year median is 53.40 vs. the industry median of 8.20, Medclair AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medclair AB's current 3-Year EBITDA Growth Rate of 180.20% is 2097.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Medclair AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medclair AB's current 3-Year EBITDA Growth Rate is 180.20%, which is 237% above median its own 10-year median of 53.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medclair AB stock overvalued right now?
Based on GuruFocus' analysis, Medclair AB (NGM:MCLR) is currently considered Modestly Overvalued. The stock's GF Value™ is kr2.38, compared to a current price of kr2.89 — trading 21.4% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 180.20%, which is 237% above median its 10-year median of 53.40 and 2097.6% above the Medical Devices & Instruments industry median of 8.20. Medclair AB's overall GF Score™ is 71/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Medclair AB (NGM:MCLR), the current 3-Year EBITDA Growth Rate is 180.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medclair AB (NGM:MCLR) Overvalued in 2026?
Based on GuruFocus' analysis, Medclair AB stock appears to be overvalued.
The current stock price of kr2.89 is trading 21.4% above its estimated GF Value™ of kr2.38.
GuruFocus considers Medclair AB to be Modestly Overvalued.
Key valuation signals for NGM:MCLR:
3-Year EBITDA Growth Rate: 180.20% (237% above median its 10-year median of 53.40)
GF Value™: kr2.38 vs. price of kr2.89 (21.4% above fair value)
Industry Position: 2097.6% above the Medical Devices & Instruments median (#2 of 692)
No single metric tells the full story. See the NGM:MCLR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medclair AB operates in healthcare industry. The company has two units: Central Destruction Unit (CDU) and Mobile Destruction Unit (MDU) decomposes the nitrous oxide entering the unit, transforming it to nitrogen (N2) och oxygen (O2). It also provide solutions for various N2O methods such as double mask, single mask, mouthpiece, or free flow, which ensures a safe work environment for healthcare professionals.
71GF Score
Get the complete analysis for NGM:MCLR
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:MCLR has been successfully added to your 
